DOCSLIB.ORG

CVMP Assessment Report for Nexgard Combo (EMEA/V/C/005094/0000) INN: Esafoxolaner / Eprinomectin / Praziquantel

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CVMP Assessment Report for Nexgard Combo (EMEA/V/C/005094/0000) INN: Esafoxolaner / Eprinomectin / Praziquantel 26 November 2020 EMA/640861/2020 Veterinary Medicines Division Committee for Medicinal Products for Veterinary Use CVMP assessment report for NexGard Combo (EMEA/V/C/005094/0000) INN: esafoxolaner / eprinomectin / praziquantel Assessment report as adopted by the CVMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Introduction ................................................................................................ 4 Scientific advice.......................................................................................................... 5 MUMS/limited market status ........................................................................................ 5 Part 1 - Administrative particulars .............................................................. 5 Detailed description of the pharmacovigilance system ..................................................... 5 Manufacturing authorisations and inspection status ......................................................... 5 Overall conclusions on administrative particulars ............................................................ 6 Part 2 - Quality ........................................................................................... 6 Composition ............................................................................................................... 6 Containers ................................................................................................................. 6 Development pharmaceutics ........................................................................................ 6 Method of manufacture ............................................................................................... 7 Control of starting materials ......................................................................................... 7 Active substance ........................................................................................................ 7 Excipients ................................................................................................................ 10 Specific measures concerning the prevention of the transmission of animal spongiform encephalopathies ...................................................................................................... 11 Control tests on the finished product ........................................................................... 11 Stability................................................................................................................... 11 Overall conclusions on quality .................................................................................... 12 Part 3 – Safety .......................................................................................... 12 Safety documentation ............................................................................................... 12 Pharmacodynamics ................................................................................................... 12 Pharmacokinetics ...................................................................................................... 13 Toxicological studies ................................................................................................. 13 Single dose toxicity ................................................................................................... 14 Repeat dose toxicity .................................................................................................. 14 Tolerance in the target species of animal ..................................................................... 15 Reproductive toxicity ................................................................................................. 16 Genotoxicity ............................................................................................................. 17 Carcinogenicity ......................................................................................................... 17 Studies of other effects ............................................................................................. 17 Excipients ................................................................................................................ 18 User safety .............................................................................................................. 18 Environmental risk assessment .................................................................................. 20 Residues documentation ............................................................................................ 20 Overall conclusions on the safety documentation .......................................................... 20 Part 4 – Efficacy ........................................................................................ 21 Pharmacodynamics ................................................................................................... 22 Development of resistance ......................................................................................... 23 Pharmacokinetics ...................................................................................................... 24 Justification of fixed combination ................................................................................ 25 Dose justification/ determination / finding studies ......................................................... 25 CVMP assessment report for NexGard Combo (EMEA/V/C/005094/0000) EMA/640861/2020 Page 2/46 Dose confirmation studies .......................................................................................... 25 Target animal tolerance ............................................................................................. 31 Clinical field trials ..................................................................................................... 35 Overall conclusion on efficacy ..................................................................................... 40 Part 5 – Benefit-risk assessment .............................................................. 42 Introduction ............................................................................................................. 42 Benefit assessment ................................................................................................... 42 Direct therapeutic benefit .......................................................................................... 42 Additional benefits .................................................................................................... 43 Risk assessment ....................................................................................................... 43 Risk management or mitigation measures ................................................................... 44 Evaluation of the benefit-risk balance .......................................................................... 44 Conclusion ............................................................................................................... 46 CVMP assessment report for NexGard Combo (EMEA/V/C/005094/0000) EMA/640861/2020 Page 3/46 Introduction On 5 November 2020, the CVMP adopted an opinion and CVMP assessment report. On 06 January 2021, the European Commission adopted a Commission Decision granting the marketing authorisation for NexGard Combo. On 21 May 2019, an application for a marketing authorisation to the European Medicines Agency (The Agency) for NexGard Combo was submitted, through the centralised procedure under Article 3(2)(a) of Regulation (EC) No 726/2004 (optional scope). The initial applicant for the product was Merial; however, due to a company merger, the applicant changed during the procedure to Boehringer Ingelheim Vetmedica GmbH. The eligibility to the centralised procedure was agreed upon by the CVMP on 20 July 2018 as NexGard Combo contains a combination of active substances (esafoxolaner, eprinomectin and praziquantel), one of which (esafoxolaner) was not authorised as a veterinary medicinal product in the Union on the date of entry into force of Regulation (EC) No 726/2004. At the time of submission, the applicant applied for the following indications: “For cats with, or at risk from mixed infestations by cestodes, nematodes and ectoparasites. The veterinary medicinal product is exclusively indicated when all three groups are targeted at the same time. Ectoparasites: Treatment and prevention of infestations by fleas (Ctenocephalides felis). One treatment prevents further infestations for at least one month. Prevention of environmental flea contamination by preventing egg laying for over a month. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). Treatment and prevention of infestations by ticks (Rhipicephalus sanguineus, Ixodes ricinus, Ixodes scapularis, Amblyomma americanum). One treatment prevents further infestations for at least one month. Treatment of ear mange (Otodectes cynotis). Gastro-intestinal cestodes: Treatment of infestations with tapeworms (Dipylidium caninum, Taenia taeniaeformis, Echinococcus multilocularis, Joyeuxiella pasqualei (adult), and Joyeuxiella fuhrmanni
Load more

Recommended publications
  • Evaluation of Fluralaner and Afoxolaner Treatments to Control Flea
    Dryden et al. Parasites & Vectors (2016) 9:365 DOI 10.1186/s13071-016-1654-7 RESEARCH Open Access Evaluation of fluralaner and afoxolaner treatments to control flea populations, reduce pruritus and minimize dermatologic lesions in naturally infested dogs in private residences in west central Florida USA Michael W. Dryden1*, Michael S. Canfield2, Kimberly Kalosy1, Amber Smith1, Lisa Crevoiserat1, Jennifer C. McGrady1, Kaitlin M. Foley1, Kathryn Green2, Chantelle Tebaldi2, Vicki Smith1, Tashina Bennett1, Kathleen Heaney3, Lisa Math3, Christine Royal3 and Fangshi Sun3 Abstract Background: A study was conducted to evaluate and compare the effectiveness of two different oral flea and tick products to control flea infestations, reduce pruritus and minimize dermatologic lesions over a 12 week period on naturally infested dogs in west central FL USA. Methods: Thirty-four dogs with natural flea infestations living in 17 homes were treated once with a fluralaner chew on study day 0. Another 27 dogs living in 17 different homes were treated orally with an afoxolaner chewable on day 0, once between days 28–30 and once again between days 54–60. All products were administered according to label directions by study investigators. Flea populations on pets were assessed using visual area counts and premise flea infestations were assessed using intermittent-light flea traps on days 0, 7, 14, 21, and once between days 28–30, 40–45, 54–60 and 82–86. Dermatologic assessments were conducted on day 0 and once monthly. Pruritus assessments were conducted by owners throughout the study. No concurrent treatments for existing skin disease (antibiotics, anti-inflammatories, anti-fungals) were allowed.
    [Show full text]
  • NEXGARD SPECTRA, INN-Afoxolaner-Milbemycin Oxime
    EMA/704200/2014 EMEA/V/C/003842 Nexgard Spectra (afoxolaner/milbemycin oxime) An overview of Nexgard Spectra and why it is authorised in the EU What is Nexgard Spectra and what is it used for? Nexgard Spectra is a veterinary medicine used to treat infestations with fleas, ticks, as well as demodectic and sarcoptic mange (skin infestations caused by two different types of mites) in dogs when prevention of heartworm disease (caused by a worm that infects the heart and blood vessels and is transmitted by mosquitoes), lungworm disease, eye worm and/or treatment of gut worms (hookworms, roundworms and whipworm) is also required. Nexgard Spectra contains the active substances afoxolaner and milbemycin oxime. How is Nexgard Spectra used? Nexgard Spectra is available as chewable tablets in five different strengths for use in dogs of different weights. It can only be obtained with a prescription. The appropriate strength of tablets should be used according to the dog’s weight. Treatment for fleas and ticks should be repeated at monthly intervals during the flea or tick seasons; Nexgard Spectra can be used as part of the seasonal treatment of fleas and ticks in dogs infected with gut worms. A single dose of Nexgard Spectra is given to treat gut worms. After which, further flea and tick treatment should be continued with a monovalent product containing a single active substance. For demodectic mange, treatment should be repeated monthly until the mange is successfully treated (as confirmed by two negative skin scrapings one month apart) whereas for sarcoptic mange treatment is given monthly for two months, or longer based on clinical signs and skin scrapings.
    [Show full text]
  • Cover Memo Isoxazolines Inquires
    Name: Isoxazoline inquiries DATE:10/1/2018 This serves as the response to your Freedom of Information Act (FOIA) request for records regarding adverse event reports received for afoxolaner, fluralaner, lotilaner and sarolaner. A search of CVM’s Adverse Drug Event (ADE) database was performed on 10-01-2018. The search parameters were: Active ingredient(s): afoxolaner, fluralaner, lotilaner and sarolaner Reports received: From 09-04-2013 through 07-31-2018 Case type: Spontaneous ADE report Species: All Route of administration: All For each drug (active ingredient), we have provided the ‘CVM ADE Comprehensive Clinical Detail Report Listing’, which is a cumulative listing of adverse experiences in reports submitted to CVM. General Information about CVM’s ADE Database The primary purpose for maintaining the CVM ADE database is to provide an early warning or signaling system to CVM for adverse effects not detected during pre-market testing of FDA- approved animal drugs and for monitoring the performance of drugs not approved for use in animals. Information from these ADE reports is received and coded in an electronic FDA/CVM ADE database. CVM scientists use the ADE database to make decisions about product safety which may include changes to the label or other regulatory action. CVM’s ADE reporting system depends on detection and voluntary reporting of adverse clinical events by veterinarians and animal owners. The Center's ADE review process is complex, and for each report takes into consideration confounding factors such as: Dosage Concomitant drug use The medical and physical condition of animals at the time of treatment Environmental and management information Product defects Name: Isoxazoline inquiries DATE:10/1/2018 Extra-label (off label) uses The specifics of these complex factors cannot be addressed in the CVM ADE Comprehensive Clinical Detail Report Listing.
    [Show full text]
  • Nexgard, Afoxolaner
    13 September 2018 EMA/665923/2018 Veterinary Medicines Division CVMP assessment report for a worksharing grouped type II variation for NEXGARD SPECTRA and NexGard (EMEA/V/C/WS1338/G) International non-proprietary name: afoxolaner / milbemycin oxime; afoxolaner Assessment report as adopted by the CVMP with all information of a commercially confidential nature deleted. Rapporteur: Jeremiah Gabriel Beechinor Co-Rapporteur: Peter Hekman 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5545 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Introduction ............................................................................................ 3 1.1. Submission of the variation application ................................................................... 3 1.2. Scope of the variation ........................................................................................... 3 1.3. Changes to the dossier held by the European Medicines Agency ................................. 3 1.4. Scientific advice ................................................................................................... 3 1.5. MUMS/limited market status .................................................................................. 3 2. Scientific Overview .................................................................................
    [Show full text]
  • Top 5 Cytologic Findings in Aspirates of Enlarged
    May 2019 A Peer-Reviewed Journal | cliniciansbrief.com TOP 5 CYTOLOGIC FINDINGS IN ASPIRATES OF ENLARGED IN THIS ISSUE LYMPH NODES Top 5 Radiographic Variants Respiratory Distress & Inappetence Case Management Algorithm: Snake Envenomation Managing Aggressive & Fearful Dogs Neutropenia: A Differential Diagnosis List Volume 17 Number 5 THE OFFICIAL CLINICAL PRACTICE JOURNAL OF THE WSAVA Advantage Multi® for Dogs and for Cats (imidacloprid + moxidectin) BRIEF SUMMARY: Before using Advantage Multi ® for Dogs (imidacloprid+moxidectin) or Advantage Multi ® for Cats (imidacloprid +moxidectin), please consult the product insert, a summary of which follows: CAUTION: Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Advantage Multi for Dogs: WARNING • DO NOT ADMINISTER THIS PRODUCT ORALLY. • For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. • Children should not come in contact with the application sites for two (2) hours after application. (See Contraindications, Warnings, Human Warnings, and Adverse Reactions for more information.) INDICATIONS: Advantage Multi for Dogs is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Treats and controls Advantage Multi for Dogs kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). Advantage Multi for Dogs is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var.canis. Advantage Multi for Dogs is also indicated sarcoptic mange in dogs for the treatment and control of the following intestinal parasites species: Hookworms (Ancylostoma caninum) (Uncinaria stenocephala), Roundworms (Toxocara canis) (Toxascaris leonina) and Whipworms (Trichuris vulpis).
    [Show full text]
  • AAVP 2020 Annual Meeting Proceedings
    Proceedings AAVP American Association of Veterinary Parasitologists Progressive Solutions for Age-Old Problems Membership Directory 65th Annual Meeting Virtual Meeting June 20–23, 2020 Reproduced with permission from Dr. Russell Avramenko and Dr. John Gilleard and cover of International Journal for Parasitology 49,1 6/18/2020 7:35:12 AM American Association of Veterinary Parasitologists 65th Annual Meeting, June 20th – 23rd 2020, Virtual Meeting 2020 AAVP-Boehringer Ingelheim Distinguished Veterinary Parasitologist Sharon Patton, MS, PhD Sharon Patton was born on a farm in Watertown, TN to Virginia Bland and Charles Patton. She was the middle child with an older brother and two younger sisters. Her father was an “egg peddler” and sold eggs door to door in what is now considered the “greater Nashville” area. In the summer, Sharon went with her father to sell eggs 2 days/week – leaving at 4 am and returning around 7 pm. It was hard work for a little girl carrying buckets full of eggs door to door, but she loved it and gradually began to deliver more eggs than her father (although she always slept during the 50-mile drive home). The family moved from the farm where they were living with her grandparents to the small town of Watertown, but the egg peddling continued as did raising Black Angus cattle, and her father tending to 10,000 chickens that he managed in chicken houses on the farm. Later the family returned to the farm and built a house across the road from the grandparents’ house. Her father died while she was in college.
    [Show full text]
  • Lecture Overview Meet Kenny
    CVMA-SBCV Chapter Fall Conference and Trade Show Isoxazolines November 3rd 2019 Lecture overview ‣ Introduction ‣ Mechanism of action ‣ Disadvantage ‣ Advantages ‣ Extra-label use ‣ Implications for practice CONFIDENTIAL INFORMATION - MARS INC. 1 Meet Kenny https://www.canadianveterinarians.net/documents/wcv-summer-2019 CONFIDENTIAL INFORMATION - MARS INC. 2 Dr. Vincent Defalque Diplomate of the American College of Veterinary Dermatology North West Veterinary Dermatology Services CVMA-SBCV Chapter Fall Conference and Trade Show Isoxazolines November 3rd 2019 Meet Kenny ‣ 6 month-old intact male Australian Shepherd. ‣ Seen at North West Veterinary Dermatology Specialists in September 2015. ‣ Demodicosis lesions predominantly facial. ‣ Also had a severe secondary bacterial pyoderma caused by methicillin- resistant Staphylococcus pseudintermedius. ‣ Severe pruritus. Needed to wear an Elizabethan collar 24/7! ‣ Considering the age, but most importantly the breed of the patient (a well know ivermetin sensitive breed), I decided it was a great opportunity to treat my first case of canine demodicosis with oral fluralaner. CONFIDENTIAL INFORMATION - MARS INC. 3 Single dose of oral fluralaner before and after pictures Day 0 Day 44 CONFIDENTIAL INFORMATION - MARS INC. 4 Dr. Vincent Defalque Diplomate of the American College of Veterinary Dermatology North West Veterinary Dermatology Services CVMA-SBCV Chapter Fall Conference and Trade Show Isoxazolines November 3rd 2019 Introduction ‣ Flea and tick infestation is a major health problem in dogs and cats. ‣ Control presents an economic burden to pet owners. ‣ Recent advances in product technology have greatly expanded the available options for veterinarians and pet owners. ‣ Afoxolaner, fluralaner, lotilaner and sarolaner are novel synthetic members of the isoxazoline class of parasiticides showing activity against insects and acarines, including fleas and ticks.
    [Show full text]
  • Comparison of Efficacy, Side Effects, and Cost of Isoxasolines and Ivermectin Against Generalized Canine Demodicosis
    Comparison of Efficacy, Side Effects, and Cost of Isoxasolines and Ivermectin Against Generalized Canine Demodicosis Item Type text; Electronic Thesis Authors Leinart, Linzey Barbara Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 27/09/2021 13:42:50 Item License http://rightsstatements.org/vocab/InC/1.0/ Link to Item http://hdl.handle.net/10150/625036 COMPARISON OF EFFICACY, SIDE EFFECTS, AND COST OF ISOXASOLINES AND IVERMECTIN AGAINST GENERALIZED CANINE DEMODICOSIS By LINZEY BARBARA LEINART ____________________ A Thesis Submitted to the Honors College In Partial Fulfillment of the Bachelors degree With Honors in Veterinary Science THE UNIVERSITY OF ARIZONA M A Y 2017 Dr. Michael W. Riggs University of Arizona Honors College 2017 Approved By: _____________________________________ Dr. Michael W. Riggs, D.V.M, PhD, DACVP School of Animal and Comparative Biomedical Science Abstract Demodex canis mites are found in the normal skin microbiota of most dogs, but can result in canine demodicosis if the number of mites dramatically increases due to underlying disease, immunosurpression, genetic defect, stress, or breed association. Treating generalized Demodectic mange often requires high owner compliance over a potentially long period of time, especially when using ivermectin. Recent studies have revealed that a class of insecticides known as isoxasolines provide a better alternative for treatment of generalized demodicosis, specifically afoxolaner (NexGard®), fluralaner (Bravecto™), and sarolaner (Simparica™).
    [Show full text]
  • On the Use of Inhibitors of 4-Hydroxyphenylpyruvate
    bioRxiv preprint doi: https://doi.org/10.1101/669747; this version posted June 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 On the use of inhibitors of 4-hydroxyphenylpyruvate 2 dioxygenase as a vector-selective insecticide in the 3 control of mosquitoes 4 5 Marlon A. V. Ramirez1, Marcos Sterkel2¶*, Ademir de Jesus Martins3,4,5, José Bento 6 Pereira Lima3,4 and Pedro L. Oliveira1,4¶* 7 8 1 Laboratório de Bioquímica de Artrópodes Hematófagos, Instituto de Bioquímica Médica 9 Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. 10 2Centro Regional de Estudios Genómicos, Universidad Nacional de La Plata (CREG- 11 UNLP), Argentina. 12 3Laboratorio de Fisiologia e Controle de Artrópodes Vetores, Instituto Oswaldo Cruz, 13 FIOCRUZ, Rio de Janeiro, RJ, Brasil. 14 4Laboratório de Entomologia, Instituto de Biologia do Exército, Rio de Janeiro, RJ, Brasil. 15 5Instituto Nacional de Ciencia e Tecnologia em Entomologia Molecular (INCT-EM), 16 Brazil. 17 18 * Corresponding author 19 E-mail addresses: 20 [email protected] 21 [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/669747; this version posted June 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.
    [Show full text]
  • Insecticide Recommendations for Arkansas
    MP144 2020 TABLE OF CONTENTS Page Page Introduction Fruits and Nuts Poison Control Centers in Arkansas ...................................................................... 4 Apple and Pear ............................................................................................. 135 Blackberry and Raspberry ............................................................................ 140 Insecticide Application ............................................................................................. 4 Blueberry....................................................................................................... 143 Cherry, Peach and Plum ............................................................................... 145 General Information About Insecticides Grape ............................................................................................................ 149 Formulations and Concentrations .................................................................... 9 Home Orchard .............................................................................................. 153 Table of Weights, Measures and Dilutions ..................................................... 10 Pecan ............................................................................................................. 156 Common and Trade Names of Chemicals ...................................................... 13 Strawberry ..................................................................................................... 158 Toxicity of Certain
    [Show full text]
  • Nexgard Spectra
    Di Cesare et al. Parasites Vectors (2021) 14:143 https://doi.org/10.1186/s13071-021-04648-y Parasites & Vectors RESEARCH Open Access Efcacy of milbemycin oxime/afoxolaner chewable tablets (NEXGARD SPECTRA ®) against Capillaria aerophila and Capillaria boehmi in naturally infected dogs Angela Di Cesare1, Simone Morelli1, Giulia Morganti2, Giulia Simonato3, Fabrizia Veronesi2, Mariasole Colombo1, Michele Berlanda3, Wilfried Lebon4, Matilde Gallo1, Frederic Beugnet4 and Donato Traversa1* Abstract Background: Capillaria aerophila and Capillaria boehmi parasitize the respiratory system of wild and domestic carni- vores. Capillaria aerophila inhabits the trachea and bronchi of dogs and cats, while C. boehmi afects the nasal cavities and sinuses of dogs. In dogs the infection may be subclinical or characterized by varying respiratory distress. Methods: The present study evaluated the efcacy of an oral formulation containing milbemycin oxime and afoxolaner (NEXGARD SPECTRA ®) in dogs naturally infected with C. aerophila and/or C. boehmi from three enzootic areas of Italy. Dogs were enrolled pending fecal examination and molecular confrmation of respiratory capillarioses. Dogs were allocated in two groups: Group 1 (G1, 25 dogs), treated with a negative control product with no anthel- mintic activity (afoxolaner, NEXGARD®), and Group 2 (G2, 26 dogs), treated with NEXGARD SPECTRA ®. At the day of treatment administration (Day 0), all dogs were clinically examined. Dogs were again subjected to clinical and fecal examinations at Days 28 ( 4) and 56 ( 2). The primary criterion for treatment efcacy was the reduction of fecal Capillaria egg counts in G2± compared ±with G1. The regression of/recovery from baseline clinical signs was considered as a further efcacy criterion.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]